


Graphical Abstract

Synthesis of Novel Chalcogen-Containing Derivatives of DNA Nucleobases

Guoxiong Hua, Junyi Du, David B. Cordes, Alexandra M. Z. Slawin, J. Derek Woollins*



A number of novel DNA nucleobase derivatives containing chalcogens (S, Se and Te) has been synthesized in satisfactory yields.



Efficient Synthesis of Novel Chalcogen-Containing Derivatives of DNA Nucleobases

Guoxiong Hua, Junyi Du, David B. Cordes, Alexandra M. Z. Slawin, J. Derek Woollins*

EaStCHEM School of Chemistry, University of St Andrews, Fife, KY16 9ST, UK

*Corresponding author. Tel.: (+44)-1334-463384; email: jdw3@st-and.ac.uk

ARTICLE INFO

Article history:

Received
Received in revised form
Accepted
Available online

Keywords:

DNA nucleobases
9-(2-Bromoethyl)adenine
Adenine derivatives
Chalcogens
Woollins' reagent

ABSTRACT

The formation of a library of chalcogen-containing DNA nucleobase derivatives is presented. Reacting easily accessible 9-(2-bromoethyl)adenine with chalcogen-containing nucleophilic reagents led to a series of novel heteroatom derivatives incorporating S, Se and Te atoms prepared in satisfactory yields. Two representative X-ray structures are reported.

2009 Elsevier Ltd. All rights reserved.

1. Introduction

Selenium, an essential micronutrient for humans and animals,^{1–6} is a trace element nutrient that functions as selenocysteine for the reduction of antioxidant enzymes such as glutathione peroxidases,^{7,8} thioredoxin reductase,⁹ and thyroid hormone deiodinases.¹⁰ The entire selenoprotein gene population, designated the selenoproteome, has been identified in humans and rodents,¹¹ and numerous selenoprotein genes have functions in development and health.¹² Selenoproteins are also involved in different human genetic disorders.¹² The antioxidant activity of selenium plays a protective role in 50 human diseases, including prostate, lung, and intestine/colon cancer, immunodeficiency, and heart diseases.^{13–16} It is well known that adenine moiety provides the hydrogen bond with a variety of biological molecules and contributes to the diverse biological functions such as molecular recognition in DNA replication and protein biosynthesis.¹⁷ Adenine derivatives substituted in position 9 have potent cyclic nucleotide phosphodiesterase (PDE) inhibition properties with high selectivity toward PDE-4.¹⁸ For instance, the 9-(2-fluorobenzyl)-*N*₆-methyladenine has been found to be used as a potent anticonvulsant,¹⁹ anxiolytic and sedative properties,²⁰ and was a relatively potent PDE-4 inhibitor (IC₅₀-2.0 mM).²¹ Furthermore, initial structure activity relationship (SAR) studies around 9-substituted adenine derivatives allowed us to identify 9-(2-fluorobenzyl)-*N*₆-methyl-2-trifluoromethyladenine, as a potent PDE-4 inhibitor (IC₅₀-0.042 mM), with a high selectivity vs PDE-3.²¹ Moreover, 9-(2-fluorobenzyl)-*N*₆-methyl-2-trifluoromethyladenine elicited also anti-inflammatory properties,²² and marked dose-dependent inhibition of arachidonate release from human mononuclear cells stimulated with *N*-formyl-Met-Leu-Phe, a suitable model to investigate the in vitro anti-inflammatory activity of PDE-4

inhibitors.²³ In addition, 9-(2-fluorobenzyl)-*N*₆-methyl-2-trifluoromethyladenine and several 9-substituted adenine derivatives elicited a concentration-dependent inhibition of the TNF α release from mononuclear cells stimulated with lipopolysaccharide (LPS).²³ To our knowledge, chalcogen-containing derivatives substituted in position 9 have not been reported. In this paper, we report the synthesis of a series of chalcogen-containing adenine derivatives substituted in position 9 and two related X-ray single crystal structures.


2. Results and Discussion

9-(2-Bromoethyl)adenine (**2**) was obtained from unprotected adenine (**1**) according to the literature method.²⁴ Starting from unprotected adenine (**1**), selective alkylation with dibromoethane in the presence of dry K₂CO₃ in DMF gave the derivative **2** in 45% isolated yield. **2** was applied to the synthesis of many kinds of chalcogen-containing molecules as a starting material as shown in Scheme 1. Reaction of **2** with 0.5 equiv of sodium selenide or sodium telluride in DMF at room temperature for 40 h gave the corresponding 9,9'-(selenobis(ethane-2,1-diyl))bis(9*H*-purin-6-amine) (**3**) and 9,9'-(tellurobis(ethane-2,1-diyl))bis(9*H*-purin-6-amine) (**4**) in respective 95% and 68% yields. The reactions can be accelerated by warming up the reaction solutions; however, brown selenium or dark tellurium being found in the resulting suspension resulted in reduced yields. Furthermore, lower yields were obtained when the reactions were carried out in ethanol/THF (50/50, v/v), DMF seemed to perform much better. The use of an excess of 9-(2-bromoethyl)adenine also improves yields and conversions. Treating a suspension of potassium selenocyanate with 9-(2-bromoethyl)adenine in dry acetone at 60°C led to the formation of 9-(2-selenocyanatoethyl)adenine (**5**) in 93% yield. Reacting

diphenyldisulfide or diphenyldiselenide with an excess of NaBH_4 in dry THF/EtOH at room temperature, followed by addition of 9-(2-bromoethyl)adenine followed by stirring at room temperature for 24 h gave rise to 9-(2-(phenylthio)ethyl)adenine (**6**) and 9-(2-(phenylselenyl)ethyl)adenine (**7**) 95% and 80% yields respectively. It is noteworthy that the sulfur starting material proved to be more reactive than its selenium analogue.


In addition, the reaction of 9-(2-bromoethyl)adenine with an equivalent of 1-(naphthalen-2-yl)-2-selenocyanateethanone, which was obtained from a modified literature method,²⁵ and NaBH_4 in dry

THF/EtOH gave 2-((2-(6-amino-9H-purin-9-yl)ethyl)selenyl)-1-(naphthalen-2-yl)ethanone (**8**) in 99% yield. Similarly, 11-((2-(6-Amino-9H-purin-9-yl)ethyl)selenyl)undecan-1-ol (**9**) was formed from 11-selenocyanatoundecan-1-ol with 9-(2-bromoethyl)adenine under the identical reaction conditions in 99% yield. Both reactions are very straightforward. Furthermore, the reaction of 9-(2-bromoethyl)adenine with one equivalent of potassium selenocyanate in ethanol, followed by the hydrolysis with aqueous solution of NaOH produced 2-(6-amino-9H-purin-9-yl)ethyl diselane (**10**) from in 87% yield.



Scheme 1. Synthesis of a series of new selenium-containing derivatives **2** - **10** of adenine

The synthesis of 9-(2-((2-bromobenzyl)selenyl)ethyl)adenine (**11**) can be achieved from 9-(2-bromoethyl)adenine by two routes as shown in Scheme 2. Stirring a suspension of 1,2-bis(2-bromobenzyl)diselane (which was prepared following a literature method²⁶) with NaBH_4 and 9-(2-bromoethyl)adenine in a dry mixed medium of THF/EtOH (1 : 1) at room temperature for 20 h led to the formation of 9-(2-((2-bromobenzyl)selenyl)ethyl)adenine (**11**) in 86% yield. Alternately, mingling 1-bromo-2-(selenocyanatomethyl)benzene with NaBH_4 and 9-(2-bromoethyl)adenine in dry THF/EtOH (1 : 1) at room temperature for 20 h gave the same product in 61% yield. It is noteworthy that 1,2-bis(2-bromobenzyl)diselane proved to be more efficient starting material than 1-bromo-2-(selenocyanatomethyl)benzene for the synthesis of the targeted product with high yield. Both reactions resulted in the expected products without noticeable byproduct.




Scheme 2. Synthesis of 9-(2-((2-bromobenzyl)selenyl)ethyl)-9H-purin-6-amine **11**

Breaking the four-membered ring in Woollins' reagent with two molar equivalents of sodium alkanolates formed the sodium *O*-alkyl

phenylphosphonodiselenoates **12** - **14** in high yields,²⁷ the latter were stirred with an equivalent of 9-(2-bromoethyl)adenine in dry THF overnight at room temperature to generate *Se*-(2-(6-amino-9H-purin-9-yl)ethyl) *O*-alkyl phenylphosphonodiselenoates **15** - **17** in 69% - 87% yields, respectively, as shown in Scheme 3. To reduce the probability of any diselenide byproduct formation, these reactions were performed in an inert atmosphere. It is noteworthy that neither coupling of two *O*-alkyl phenylphosphonodiselenoate molecules nor decomposed selenium were detected.

Compounds **3** - **11**, **15** - **17** were spectrally characterized by multi-nuclear NMR and IR spectroscopy and accurate mass measurement. All of new compounds showed the anticipated molecular ion peaks $[\text{M}+\text{H}]^+$ or $[\text{M}+\text{Na}]^+$ and were confirmed by satisfactory accurate mass measurements. Two stereoisomers were observed by multinuclear NMR in compound **9**. The ^{77}Se NMR chemical shifts in compounds **3**, **5**, **7** - **11** fall within the range from 121.6 to 297.9 ppm, the highest ^{77}Se NMR chemical shift value is one of two isomers in compound **9** with long alkyl chain alcohol group, whilst the lowest ^{77}Se NMR chemical shift value is the compound **3** with a symmetric conformation in Se atom centre. Surprisingly, one of two isomers in compound **9** has very low ^{77}Se NMR chemical shift (140.0 ppm). Another sample having high ^{77}Se NMR chemical shift value (282.8 ppm) is compound **10**, in which also adopts a symmetric conformation around the Se-Se bridge. With the similar conformation as compound **3**, the ^{125}Te NMR chemical shift value in compound **4** is 199.3 ppm. The ^{31}P NMR spectra of **15** - **17** show sharp singlets in the range of 79.3 - 83.6 ppm, flanked by two pairs of selenium satellites with ^{31}P - ^{77}Se coupling constants in

the ranges of 434 – 439 Hz and 825 – 831 Hz, indicating the presence of both P-Se single bond and P=Se double bond in these three compounds. This was further supported by the ^{77}Se NMR spectra which showed two pairs of doublets in the range of 307.8 – 338.6 ppm and -105.9 – -92.1 ppm with matching ^{31}P - ^{77}Se coupling constants in compounds **15** – **17**. The ^1H NMR spectra of **15** – **17** showed two strong singlets ranging from 7.94 – 8.38 ppm, accompanied by singlet peaks in the range of 7.15 – 7.53 ppm for the adenine NH_2 groups, indicated the presence of adenine ring in the molecules. The presence of the adenine rings can further confirmed by their special five carbon chemical shift values in the ^{13}C NMR spectra.



Scheme 3. Synthesis of Se-(2-(6-amino-9H-purin-9-yl)ethyl) O-alkyl phenylphosphonodiselenoates **15** - **17**




Figure 1. (a) Single crystal X-ray structure of 1-(naphthalen-2-yl)-2-selenocyanatoethanone **16**. Selected bond lengths (Å) and angles ($^\circ$) (esds in parentheses): Se(1)-P(1) 2.253(6), Se(2)-P(1) 2.118(5), Se(1)-C(9) 1.936(14), P(1)-C(1) 1.640(2), P(1)-O(1) 1.612(13), O(1)-C(7) 1.420(3); P(1)-Se(1)-C(9) 100.1(5), Se(1)-P(1)-O(1) 103.5(6), Se(2)-P(1)-O(1) 113.2(6), O(1)-P(1)-C(1) 101.8(9), Se(1)-P(1)-Se(2) 114.9(2), Se(1)-P(1)-C(1) 107.5(8), Se(2)-P(1)-C(1) 114.6(8), P(1)-O(1)-C(7) 124.5(16), Se(1)-C(9)-C(1) 114.5(8); (b) shows the hydrogen bonding of intermolecule within **16**.

Single crystals of **16** (colorless) and **17** (colorless) obtained from diffusion of hexane into dichloromethane solutions of the compounds in air at room temperature were investigated by X-ray diffraction methods and the structures of two compounds were

determined.²⁸ The structures of **16** (Figure 1a) and **17** (Figure 2a) are in the triclinic space group *P-1* though **17** contains two independent molecules. The structural conformations have the phenyl ring and the adenine ring inclined to one another at 75.85° for **16** and 55.45° for **17**. The P(1)-Se(1)-Se(2) mean planes are nearly perpendicular to the Se(1)-C-C mean planes (88.26° for **16** and 86.35° for **17**). The P(1)-Se(1) and P(1)-Se(2) distances [2.253(6) and 2.118(5) Å for **16**, 2.246(2) and 2.081(2) Å for **17**] are typical P-Se single bond and P=Se double bond characters, comparable to that in the similar structures.²⁹




Figure 2. (c) Single crystal X-ray structure of 1-(naphthalen-2-yl)-2-selenocyanatoethanone **17**. Selected bond lengths (Å) and angles ($^\circ$) (esds in parentheses): Se(1)-P(1) 2.246(2), Se(2)-P(1) 2.081(2), Se(1)-C(9) 1.938(8), P(1)-C(11) 1.774(8), P(1)-O(1) 1.609(8), O(1)-C(8) 1.428(11); P(1)-Se(1)-C(1) 98.7(2), Se(1)-P(1)-O(1) 103.6(3), Se(2)-P(1)-O(1) 116.8(3), O(1)-P(1)-C(11) 97.9(4), Se(1)-P(1)-Se(2) 114.14(9), Se(1)-P(1)-C(11) 107.3(3), Se(2)-P(1)-C(11) 115.4(3), P(1)-O(1)-C(8) 124.7(6), Se(1)-C(1)-C(2) 114.1(5); (d) shows the hydrogen bonding of intermolecule within **17**.

In conclusion, a series of new chalcogen-containing derivatives of DNA nucleobases having the adenine functionality were successfully prepared and characterized. Reaction of 9-(2-bromoethyl) adenine with sodium selenide, sodium telluride, potassium selenocyanate, diphenyldisulfide/ NaBH_4 , diphenyldiselenide/ NaBH_4 , 1-(naphthalen-2-yl)-2-selenocyanatoethanone and 11-selenocyanatoundecan-1-ol with 9-(2-bromoethyl) adenine resulted in the corresponding chalcogen-containing heteroatom compounds in good to excellent yields. Furthermore, treating 9-(2-bromoethyl) adenine with three Woollins' reagent derivatives of alcohols led to the expected formation of three phosphorus-selenium heteroatom compounds in excellent yields. The new chalcogen-containing DNA nucleobases derivatives might provide a valuable addition to the library of selenium-containing heteroatom compounds known.

3. Experimental section

3.1. General

Unless otherwise stated, all reactions were carried out under an oxygen free nitrogen atmosphere using pre-dried solvents and standard Schlenk techniques, subsequent chromatographic and work up procedures were performed in air. ^1H (270 MHz), ^{13}C (67.9 MHz), ^{31}P - $\{^1\text{H}\}$ (109 MHz) and ^{77}Se - $\{^1\text{H}\}$ (51.4 MHz referenced to external Me_2Se) NMR spectra were recorded at 25 °C (unless stated otherwise) on a JEOL GSX 270. IR spectra were recorded as KBr pellets in the range of 4000-250 cm^{-1} on a Perkin-Elmer 2000 FTIR/Raman spectrometer. Mass spectrometry was performed by the EPSRC National Mass Spectrometry Service Centre, Swansea and the University of St Andrews Mass Spectrometry Service. X-ray crystal structures were determined for compounds **16** and **17** at -148(1) °C on a Rigaku ACTOR-SM, Saturn 724 CCD area detector [the St Andrews Automated Robotic Diffractometer (STANDARD)]³¹ with SHINE optic using Mo K α radiation ($k = 0.71073 \text{ \AA}$). The data were corrected for Lorentz, polarisation and absorption. The data was collected and processed using CrystalClear (Rigaku).³² The structures were solved by direct methods³³ and expanded using Fourier techniques.³⁴ Hydrogen atoms were refined using the riding model. All calculations were performed using the CrystalStructure³⁵ and SHELXL 97.³⁶ These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge Crystallographic Data centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax (+44) 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk. CCDC 985908-985919

3.2. Synthesis

3.2.1. Synthesis of 9,9'-(Selenobis(ethane-2,1-diyl))bisadenine (3).

A mixture of sodium selenide (0.127 g, 1.0 mmol) and 9-(2-bromoethyl)adenine (0.482 g, 2.0 mmol) in 10 mL of dry DMF was stirred at room temperature for 40 h. Upon filtering to remove the solid the filtrate was washed with water and extracted with dichloromethane (3x50 mL). The combined organic layer was dried over Na_2SO_4 . After evaporative removal of solvent the crude product was purified by column chromatography (silica gel) with 15% MeOH in dichloromethane as eluent to give 0.385 g as a peach yellow solid in 95% yield. Mp. 193 - 195 °C. Selected IR (KBr, cm^{-1}): 1680(s), 1655(s), 1602(s), 1574(m), 1485(s), 1417(s), 1328(s), 1308(s), 1252(m), 1224(m), 1074(m), 796(m), 650(s). ^1H NMR (DMF- d_7 , δ), 8.23 (s, 2H, adenine-H), 8.22 (s, 2H, adenine-H), 7.35 (s, 4H, NH_2), 4.53 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 4H, CH_2), 3.18 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 4H, CH_2) ppm. ^{13}C NMR (DMF- d_7 , δ), 156.6 (adenine-C), 152.9 (adenine-C), 150.1 (adenine-C), 141.1 (adenine-C), 119.5 (adenine-C), 43.7 (CH_2), 22.5 (CH_2) ppm. ^{77}Se NMR (DMF- d_7 , δ), 121.6 ppm. Mass spectrum [Cl^+ , m/z]: 405 [$\text{M}+\text{H}^+$]⁺. Accurate mass measurement [Cl^+ , m/z]: 405.0799 [$\text{M}+\text{H}^+$]⁺, calculated mass for $\text{C}_{14}\text{H}_{17}\text{N}_{10}\text{Se}$: 405.0797.

3.2.2. Synthesis of 9,9'-(Tellurobis(ethane-2,1-diyl))bisadenine (4).

A suspension of sodium telluride (0.176 g, 1.0 mmol) and 9-(2-bromoethyl)adenine (0.482 g, 2.0 mmol) in 10 mL of dry DMF was stirred at room temperature for 40 h. Upon filtering to remove the solid the filtrate was washed with water and extracted with dichloromethane (3x50 mL). The combined organic layer was dried over Na_2SO_4 . After evaporative removal of solvent the crude product was purified by column chromatography (silica gel) with 15% MeOH in dichloromethane as eluent to give 0.310 g as a mustard yellow solid in 68% yield. Mp. 196 - 198 °C. Selected IR (KBr, cm^{-1}): 1654(s), 1598(s), 1573(m), 1482(s), 1414(s), 1331(s), 1308(s), 1247(s), 1072(m), 1008(m), 796(m), 724(m), 645(s). ^1H NMR (DMF- d_7 , δ), 8.22 (s, 2H, adenine-H), 8.20 (s, 2H, adenine-H), 7.32 (s, 4H, NH_2), 4.59 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 4H, CH_2), 3.21 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 4H, CH_2) ppm. ^{13}C NMR (DMF- d_7 , δ), 156.6 (adenine-C), 152.9 (adenine-C), 150.0 (adenine-C), 140.8 (adenine-C), 119.5 (adenine-C), 45.7(CH_2), 1.9(CH_2) ppm. ^{125}Te NMR (DMF- d_7 , δ), 199.3 ppm. Mass spectrum [Cl^+ , m/z]: 455 [$\text{M}+\text{H}^+$]⁺. Accurate mass

measurement [Cl^+ , m/z]: 455.0681 [$\text{M}+\text{H}^+$]⁺, calculated mass for $\text{C}_{14}\text{H}_{17}\text{N}_{10}\text{Te}$: 455.0695.

3.2.3. Synthesis of 9-(2-Selenocyanatoethyl)adenine (5).

A suspension of potassium selenocyanate (0.145 g, 1.0 mmol) in 30 mL of dry acetone was heated to 60 °C, and 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) in 5 mL of dry acetone was slowly added dropwise. The resulting mixture was stirred at 60 °C for another 7 h. Upon cooling to room temperature the mixture was hydrolysed (10 mL water) and extracted with diethyl ether (2 x 30 mL). The ethereal layers were combined and dried over MgSO_4 overnight. The solvent was evaporated *in vacuo* and the residue was purified by silica gel column (dichloromethane as eluent) to give 0.250 g as a pale purple solid in 93% yield. Mp. 210 - 212 °C. Selected IR (KBr, cm^{-1}): 1675(s), 1645(m), 1607(s), 1573(m), 1478(m), 1420(m), 1331(m), 1306(m), 1235(m), 1072(m), 1016(m), 670(m), 599(m), 540(m), 504(m). ^1H NMR (DMF- d_7 , δ), 8.25 (s, 1H, adenine-H), 8.22 (s, 1H, adenine-H), 7.33 (s, 2H, NH_2), 4.74 (t, $J(\text{H,H}) = 6.6 \text{ Hz}$, 2H, NCH_2), 3.73 (t, $J(\text{H,H}) = 6.6 \text{ Hz}$, 2H, SeCH_2) ppm. ^{13}C NMR (DMF- d_7 , δ), 156.6 (adenine-C), 152.8 (adenine-C), 150.2 (adenine-C), 141.1 (adenine-C), 119.5 (adenine-C), 103.4 ($\text{C}\equiv\text{N}$), 44.2 (NCH_2), 29.3 (SeCH_2) ppm. ^{77}Se NMR (DMF- d_7 , δ), 197.1 ppm. Mass spectrum [Cl^+ , m/z]: 269 [$\text{M}+\text{H}^+$]⁺. Accurate mass measurement [Cl^+ , m/z]: 269.0046 [$\text{M}+\text{H}^+$]⁺, calculated mass for $\text{C}_8\text{H}_8\text{N}_6\text{SeH}$: 269.0048.

3.2.4. Synthesis of 9-(2-(Phenylthio)ethyl)adenine (6).

A suspension of diphenyldisulfide (0.107 g, 0.5 mmol) and NaBH_4 (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH was stirred at room temperature until a pale yellow solution was formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was added. The mixture was stirred at room temperature for 24 h. Upon evaporating to remove solvent the residue was purified by silica gel column (1 : 4 methanol/dichloromethane as eluent) to give 0.256 g as a white solid in 95% yield. Mp. 150 - 152 °C. Selected IR (KBr, cm^{-1}): 1683(vs), 1607(vs), 1574(s), 1477(s), 1418(s), 1331(m), 1302(s), 1239(m), 1071(m), 1020(m), 881(m), 795(m), 747(s), 692(s). ^1H NMR (DMF- d_7 , δ), 8.27 (s, 1H, adenine-H), 8.24 (s, 1H, adenine-H), 7.48 (d, $J(\text{H,H}) = 8.0 \text{ Hz}$, 1H, Ar-H), 7.41 (d, $J(\text{H,H}) = 8.0 \text{ Hz}$, 1H, Ar-H), 7.35 (s, 2H, NH_2), 7.26-7.21 (m, 2H, Ar-H), 4.71 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 2H, NCH_2), 4.05 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 2H, SCH_2), 3.59 (s, 2H, SCH_2) ppm. ^{13}C NMR (DMF- d_7 , δ), 156.6 (adenine-C), 153.0 (adenine-C), 150.2 (adenine-C), 141.3 (adenine-C), 135.3 (Ar-C), 129.3 (Ar-C), 129.0 (Ar-C), 126.4 (Ar-C), 119.5 (adenine-C), 45.3 (NCH_2), 31.4 (SeCH_2) ppm. Mass spectrum [Cl^+ , m/z]: 272 [$\text{M}+\text{H}^+$]⁺. Accurate mass measurement [Cl^+ , m/z]: 272.0962 [$\text{M}+\text{H}^+$]⁺, calculated mass for $\text{C}_{13}\text{H}_{13}\text{N}_5\text{SH}$: 272.0964.

3.2.5. Synthesis of 9-(2-(Phenylselenanyl)ethyl)adenine (7).

A suspension of diphenyldiselenide (0.156 g, 0.5 mmol) and NaBH_4 (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH was stirred at room temperature until a pale yellow solution was formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was added. The mixture was stirred at room temperature for 24 h. Upon evaporating to remove solvent the residue was purified by silica gel column (1 : 4 methanol/dichloromethane as eluent) to give 0.256 g as a white solid in 80% yield. Mp. 149 - 150 °C. Selected IR (KBr, cm^{-1}): 1677(s), 1643(m), 1602(vs), 1575(m), 1478(s), 1417(s), 1329(m), 1305(s), 1252(m), 1229(m), 1071(m), 1-19(m), 741(m), 691(m). ^1H NMR (DMF- d_7 , δ), 8.26 (s, 1H, adenine-H), 8.24 (s, 1H, adenine-H), 7.63 (d, $J(\text{H,H}) = 8.0 \text{ Hz}$, 1H, Ar-H), 7.55 (d, $J(\text{H,H}) = 8.0 \text{ Hz}$, 1H, Ar-H), 7.36 (s, 2H, NH_2), 7.32-7.17 (m, 2H, Ar-H), 4.70 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 2H, NCH_2), 4.04 (t, $J(\text{H,H}) = 6.9 \text{ Hz}$, 2H, SeCH_2), 3.98 (s, 2H, SeCH_2) ppm. ^{13}C NMR (DMF- d_7 , δ), 156.7 (adenine-C), 152.9 (adenine-C), 150.1 (adenine-C), 141.3 (adenine-C), 141.1 (Ar-C), 132.1 (Ar-C), 129.5 (Ar-C), 127.1 (Ar-C), 119.5 (adenine-C), 45.2

(NCH₂), 31.4 (SeCH₂) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 267.7 ppm. Mass spectrum [CI⁺, m/z]: 320 [M+H]⁺. Accurate mass measurement [CI⁺, m/z]: 320.0408 [M+H]⁺, calculated mass for C₁₃H₁₃N₅SeH: 320.0409.

3.2.6. Synthesis of 2-((2-(6-Amino-9H-purin-9-yl)ethyl)selanyl)-1-(naphthalen-2-yl)ethanone (8).

A suspension of potassium selenocyanate (1.50 g, 10.3 mmol) in 30 mL of dry acetone was heated to 60 °C, and 2-bromo-1-(naphthalen-2-yl)ethanone (2.125 g, 8.57 mmol) in 10 mL of acetone was slowly added dropwise. The resulting mixture was stirred at 60 °C for another 5 h. Upon cooling to room temperature the mixture was hydrolysed (10 mL water) and extracted ether (2 x 30 mL). The ethereal layers were combined and dried over MgSO₄ overnight. The solvent was evaporated *in vacuo* and the residue was purified by silica gel column (dichloromethane as eluent) to give 2.74 g as a pale yellow solid in 99% yield. Mp. 100 - 102°C. Selected IR (KBr, cm⁻¹): 2151(m), 1656(s), 1624(m), 1468(m), 1383(m), 1356(m), 1299(m), 1177(s), 1123(m), 996(m), 941(m), 850(m), 821(s), 744(m), 586(m), 474(s). ¹H NMR (CD₂Cl₂, δ), 8.43 (s, 1H, Nap-H), 7.96-7.88 (m, 4H, Nap-H), 7.70-7.59 (m, 2H, Nap-H), 5.00 (s, 2H, SeCH₂) ppm. ¹³C NMR (CD₂Cl₂, δ), 193.3 (C=O), 136.2 (Nap-C), 132.3 (Nap-C), 131.3 (Nap-C), 131.2 (Nap-C), 129.8 (Nap-C), 129.6 (Nap-C), 129.1 (Nap-C), 128.0 (Nap-C), 127.4 (Nap-C), 123.4 (Nap-C), 102.0 (C≡N), 39.1 (Se-C) ppm. ⁷⁷Se NMR (CD₂Cl₂, δ), 155.7 ppm. Mass spectrum [CI⁺, m/z]: 293 [M+NH₄]⁺. Accurate mass measurement [CI⁺, m/z]: 293.0191 [M+NH₄]⁺, calculated mass for C₁₃H₉N₅OSeNH₄: 293.188.

A mixture of 1-(naphthalen-2-yl)-2-selenocyanateethanone (0.275 g, 1.0 mmol) and NaBH₄ (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH was stirred at room temperature until a pale yellow solution was formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was added. The mixture was stirred at room temperature for 20 h. Upon evaporating to remove solvent the residue was purified by silica gel column (1 : 4 methanol/dichloromethane as eluent) to give 0.350 g as a pale purple solid in 85% yield. Mp. 178 - 180°C. Selected IR (KBr, cm⁻¹): 1672(vs), 1600(vs), 1575(s), 1478(m), 1418(m), 1327(m), 1306(s), 1228(m), 1070(m), 1011(m), 662(s), 598(m), 542(m). ¹H NMR (DMF-d₇, δ), 8.73 (s, 1H, Nap-H), 8.26 (s, 1H, adenine-H), 8.24 (s, 1H, adenine-H), 8.05-8.03 (m, 4H, Nap-H), 7.70-7.61 (m, 2H, Nap-H), 7.38 (s, 2H, NH₂), 3.58 (s, 2H, SeCH₂), 2.92 (t, J(H,H) = 6.1 Hz, 2H, NCH₂), 2.75 (t, J(H,H) = 6.1 Hz, 2H, SeCH₂), ppm. ¹³C NMR (CD₂Cl₂, δ), 193.2 (C=O), 162.7 (adenine-C), 162.2 (adenine-C), 161.8 (adenine-C), 156.6 (adenine-C), 152.9 (adenine-C), 141.6 (Nap-C), 141.3 (Nap-C), 130.6 (Nap-C), 129.8 (Nap-C), 128.7 (Nap-C), 128.5 (Nap-C), 127.9 (Nap-C), 127.1 (Nap-C), 123.7 (Nap-C), 119.5 (Nap-C), 97.6 (C≡N), 66.5 (Se-C), 45.2 (N-C), 31.3 (Se-C) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 197.2 ppm. Mass spectrum [CI⁺, m/z]: 412 [M+H]⁺. Accurate mass measurement [CI⁺, m/z]: 412.0670 [M+H]⁺, calculated mass for C₁₉H₁₇N₅OSeH: 412.0671.

3.2.7. Synthesis of 1-((2-(6-Amino-9H-purin-9-yl)ethyl)selanyl)undecan-1-ol (9).

A mixture of potassium selenocyanate (2.88 g, 20 mmol) in 50 mL of dry acetone was heated to 60 °C, and 2-bromo-1-undecanol (5.04 g, 20 mmol) in 20 mL of acetone was added dropwise to the mixture. The resulting mixture was stirred at 60 °C for another 5 h. Upon cooling to room temperature the mixture was hydrolysed (30 mL water) and extracted with diethyl ether (2 x 50 mL). The ethereal layers were combined and dried over MgSO₄ overnight. The solvent was evaporated *in vacuo* and the residue was purified by silica gel column chromatography (dichloromethane as eluent) to give 5.50 g as a pale yellow oil in 99% yield. Selected IR (KBr, cm⁻¹): 2927(s), 2854(s), 2151(m), 1463(m), 1056(m), 722(m), 628(m), 519(w). ¹H NMR (CD₂Cl₂, δ), 5.30 (s, 1H, OH), 3.53 (t, J(H,H) = 7.4 Hz, 2H, OCH₂), 3.02 (t, J(H,H) = 7.4 Hz, 2H, SeCH₂), 1.91-1.79 (m, 4H, CH₂), 1.55-1.28 (m, 14H, CH₂) ppm. ¹³C NMR (CD₂Cl₂, δ), 101.7 (C≡N), 62.7 (OCH₂), 34.4 (SeCH₂), 32.9 (CH₂), 30.9 (CH₂), 29.9

(CH₂), 29.6 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.1 (CH₂), 28.9 (CH₂), 25.8 (CH₂) ppm. ⁷⁷Se NMR (CD₂Cl₂, δ), 207.5 ppm. Mass spectrum [ES⁺, m/z]: 300 [M+Na]⁺. Mass spectrum [CI⁺, m/z]: 278 [M+H]⁺. Accurate mass measurement [CI⁺, m/z]: 278.1018 [M+H]⁺, calculated mass for C₁₂H₂₃N₅OSeH: 278.1018.

A suspension of 11-selenocyanatoundecan-1-ol (0.277 g, 1.0 mmol) and NaBH₄ (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH was stirred at room temperature until a pale yellow solution was formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was added. The mixture was stirred at room temperature for 20 h. Upon evaporating to remove solvent the residue was purified by silica gel column chromatography (1 : 4 methanol/dichloromethane as eluent) to give 0.405 g as a white cream solid in 98% yield. Mp. 118 - 119°C. Two diastereoisomers were found in ca. 2 : 1 intensity ratio. Selected IR (KBr, cm⁻¹): 1674(m), 1642(m), 1601(s), 1575(m), 1470(s), 1419(m), 1305(s), 1253(m), 1059(s), 793(m), 716(m). ¹H NMR (DMF-d₇, δ), 8.24 (s, 1H, adenine-H), 8.21 (s, 1H, adenine-H), 7.32 (s, 1H, adenine-H), 7.26 (s, 1H, adenine-H), 6.81 (s, 2H, NH₂), 6.80 (s, 2H, NH₂), 4.92 (t, J(H,H) = 6.1 Hz, 2H, NCH₂), 4.50 (t, J(H,H) = 6.1 Hz, 2H, NCH₂), 4.39 (t, J(H,H) = 6.1 Hz, 2H, SeCH₂), 4.04 (t, J(H,H) = 6.1 Hz, 2H, SeCH₂), 3.49 (t, J(H,H) = 6.1 Hz, OCH₂), 3.11 (t, J(H,H) = 6.1 Hz, 2H, SeCH₂), 2.95 (t, J(H,H) = 6.1 Hz, OCH₂), 2.75 (s, 1Hx2, OH), 2.58 (t, J(H,H) = 6.1 Hz, 2H, SeCH₂), 1.76-1.30 (m, 18Hx2, CH₂) ppm. ¹³C NMR (DMF-d₇, δ), 162.2 (adenine-C), 161.8 (adenine-C), 156.7 (adenine-C), 156.6 (adenine-C), 152.9 (adenine-C), 152.8 (adenine-C), 141.2 (adenine-C), 141.1 (adenine-C), 119.1 (adenine-C), 119.0 (adenine-C), 61.6 (OCH₂), 45.2 (SeCH₂), 44.1 (SeCH₂), 33.2 (CH₂), 31.3 (CH₂), 30.9 (CH₂), 29.9 (CH₂), 29.8 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.3 (CH₂), 29.1 (CH₂), 26.1 (CH₂), 23.5 (CH₂), 22.3 (CH₂) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 297.9, 140.0 ppm. Mass spectrum [CI⁺, m/z]: 414 [M+H]⁺. Accurate mass measurement [CI⁺, m/z]: 414.1759 [M+H]⁺, calculated mass for C₁₈H₃₁N₅OSeH: 414.1767.

3.2.8. Synthesis of 2-(6-Amino-9H-purin-9-yl)ethyl diselane (10).

To a suspension of 9-(2-bromoethyl)adenine (0.723 g, 3.0 mmol) in 50 mL of dry ethanol was added potassium selenocyanate (0.541 g, 3.75 mmol) at 20°. The mixture was stirred at that temperature for 4 h. Then, an aqueous solution of NaOH (0.24 g, 6.0 mmol in 10 mL of water) was added to the mixture and stirring was continued for another 2 h. After extraction with dichloromethane (30 mL x 3) and washing with water (20 mL x 3), the organic layer was dried over MgSO₄. The organic residue was further purified by silica gel chromatography (1 : 5 ethyl acetate / dichloromethane as eluent) to give 0.420 g as a off-white solid in 87% isolated yield. Mp. 159 - 161°C. Selected IR (KBr, cm⁻¹): 1688(s), 1648(s), 1603(s), 1570(m), 1513(m), 1477(m), 1419(m), 1370(m), 1332(m), 1296(s), 1248(m), 1219(m), 1079(m), 998(m), 970(m), 887(m), 793(m), 712(s), 641(s), 592(m), 344(m). ¹H NMR (DMF-d₇, δ), 8.57 (s, 2H, adenine-H), 8.30 (s, 2H, adenine-H), 7.54 (s, 4H, adenine-NH₂), 6.22 (t, J(H,H) = 6.9 Hz, 4H, NCH₂), 5.18 (t, J(H,H) = 6.9 Hz, 2H, SeCH₂), 3.67 (s, 4H, SeCH₂) ppm. ¹³C NMR (DMF-d₇, δ), 162.7 (adenine-C), 156.8 (adenine-C), 153.6 (adenine-C), 139.0 (adenine-C), 119.9 (adenine-C), 45.3 (NCH₂), 31.4 (SeCH₂) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 282.8 ppm. Mass spectrum [CI⁺, m/z]: 485 [M+H]⁺. Accurate mass measurement [CI⁺, m/z]: 484.9979 [M+H]⁺, calculated mass for C₁₄H₁₆N₁₀SeH: 484.9965.

3.2.9. 9-(2-((2-Bromobenzyl)selanyl)ethyl)adenine (11).

Method 1: 1,2-Bis(2-bromobenzyl)diselane was prepared by a modified literature method.²⁶ A suspension of 1,2-bis(2-bromobenzyl)diselane (0.250 g, 0.5 mmol) and NaBH₄ (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH was stirred at room temperature until a pale yellow solution was formed, then 9-(2-

bromoethyl)adenine (0.241 g, 1.0 mmol) was added. The mixture was stirred at room temperature for 20 h. Upon evaporating to remove solvent the residue was purified by silica gel column (1 : 4 methanol/dichloromethane as eluent) to give 0.354 g as a yellowish white solid in 86% yield. **Method 2:** A mixture of 1-bromo-2-(selenocyanatomethyl)benzene (0.275 g, 1.0 mmol) and NaBH₄ (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH was stirred at room temperature until a pale yellow solution was formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was added. The mixture was allowed to stir at room temperature for 20 h. Upon evaporating to remove solvent the residue was purified by silica gel column (1 : 4 methanol/dichloromethane as eluent) to give 0.250 g as a yellowish white solid in 61% yield. M.p. 118 - 119°C. Selected IR (KBr, cm⁻¹): 1669(s), 1599(vs), 1477(s), 1416(s), 1325(m), 1306(s), 1230(m), 1069(m), 1021(m), 797(m), 759(m), 657(m). ¹H NMR (DMF-d₇, δ), 8.26 (s, 1H, adenine-H), 8.23 (s, 1H, adenine-H), 7.65-7.33 (m, 4H, Ar-H), 7.54 (s, 2H, NH₂), 4.70 (t, J(H,H) = 6.9 Hz, 2H, CH₂), 4.05 (t, J(H,H) = 6.9 Hz, 2H, CH₂), 3.59 (s, 2H, CH₂) ppm. ¹³C NMR (DMF-d₇, δ), 162.3 (adenine-C), 161.8 (adenine-C), 156.6 (adenine-C), 152.8 (adenine-C), 141.3 (Ar-C), 139.4 (Ar-C), 133.2 (Ar-C), 131.2 (Ar-C), 129.0 (Ar-C), 124.0 (Ar-C), 119.5 (adenine-C), 45.2 (NCH₂), 31.3 (SeCH₂), 26.9 (SeCH₂) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 225.4 ppm. Mass spectrum [CI⁺, m/z]: 409 [M+H]⁺. Accurate mass measurement [CI⁺, m/z]: 408.9705 [M+NH₄]⁺, calculated mass for C₁₄H₁₄BrN₅SeH: 408.9708.

3.2.10. General procedure for the synthesis of *Se*-(2-(6-amino-9*H*-purin-9-yl)ethyl) *O*-alkyl phenylphosphonodiselenoates **15** - **17**.

Small pieces of sodium (0.046 g, 2.0 mmol) were stirred in alcohol (30 mL) at room temperature until fully dissolved. To this solution Woollins' reagent (0.54 g, 1.0 mmol) was added and heated at 60 °C for 15 min. The reaction mixture was allowed to cool to room temperature and the resulting yellow solution was filtered through a small *Celite* pad. The filtrate was dried under vacuum and 30 mL of THF was added. To this solution 9-(2-bromoethyl)adenine (0.2482 g, 2.0 mmol) was added and the mixture was stirred at room temperature overnight. The resultant mixture was filtrated to remove solid and the filtration was dried *in vacuo*, the residue was purified by silica gel column (5% methanol/95% DCM) to give the corresponding products **15** - **17**.

3.2.10.1. *Se*-(2-(6-Amino-9*H*-purin-9-yl)ethyl) *O*-methyl phenylphosphonodiselenoate (**15**).

0.800 g as greyish white solid in 87% yield. M.p. 123-125°C. Selected IR (KBr, cm⁻¹): 3323(s), 3138(s), 1648(s), 1598(s), 1481(m), 1415(m), 1301(m), 1251(m), 1105(m), 1019(m), 744(m), 710(m), 687(m), 549(s), 499(s). ¹H NMR (DMF-d₇, δ), 8.26 (s, 1H, adenine-H), 8.22 (s, 1H, adenine-H), 7.69-7.58 (m, 2H, Ar-H), 7.47-7.37 (m, 3H, Ar-H), 7.32 (s, 2H, NH), 5.14 (d, J(P,H) = 12.0 Hz, 3H, OCH₃), 4.54-4.49 (m, 2H, NCH₂), 3.42-3.29 (m, 2H, SeCH₂) ppm. ¹³C NMR (DMF-d₇, δ), 157.0 (adenine-C), 153.8 (adenine-C), 153.0 (adenine-C), 141.5 (adenine-C), 139.3 (Ar-C), 133.3 (Ar-C), 130.7 (Ar-C), 128.0 (Ar-C), 119.7 (adenine-C), 53.1 (OCH₃), 43.5 (NCH₂), 31.7 (SeCH₂) ppm. ³¹P NMR (DMF-d₇, δ), 83.6 (s, J(P,Se) = 439 Hz, J(P,Se) = 831 Hz) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 307.8 (d, J(P,Se) = 439 Hz), -105.9 (d, J(P,Se) = 830 Hz) ppm. Mass spectrum [APCI⁺, m/z]: 462 [M+H]⁺. Accurate mass measurement [APCI⁺, m/z]: 461.9493 [M+NH₄]⁺, calculated mass for C₁₄H₁₆N₅OPSe₂H: 461.9498.

3.2.10.1. *Se*-(2-(6-Amino-9*H*-purin-9-yl)ethyl) *O*-ethyl phenylphosphonodiselenoate (**16**).

0.740 g as white solid in 78% yield. M.p. 157-159°C. Selected IR (KBr, cm⁻¹): 3333.9(m), 3147(m), 1649(vs), 1596(vs), 1576(s),

1483(s), 1437(m), 1416(m), 1354(m), 1326(m), 1309(m), 1223(s), 1105(m), 1015(s), 943(s), 796(m), 740(m), 685(m), 645(m), 601(m), 549(s), 493(s). ¹H NMR (DMF-d₇, δ), 8.05 (s, 1H, adenine-H), 7.94 (s, 1H, adenine-H), 7.87-7.76 (m, 2H, Ar-H), 7.50-7.46 (m, 3H, Ar-H), 7.15 (s, 2H, NH₂), 4.35 (dt, J(H,H) = 6.6 Hz, J(P,H) = 1.7 Hz, 2H, NCH₂), 4.14-3.90 (m, 2H, OCH₂), 3.27-3.18 (m, 2H, SeCH₂), 1.22 (t, J(H,H) = 7.0 Hz, 3H, CH₃) ppm. ¹³C NMR (DMF-d₇, δ), 156.9 (adenine-C), 153.2 (adenine-C), 150.4 (adenine-C), 141.2 (adenine-C), 137.5 (Ar-C), 133.2 (Ar-C), 130.6 (Ar-C), 129.2 (Ar-C), 119.8 (adenine-C), 63.6 (OCH₂), 43.4 (NCH₂), 31.7 (SeCH₂), 15.6 (CH₃) ppm. ³¹P NMR (DMF-d₇, δ), 79.3 (s, J(P,Se) = 436 Hz, J(P,Se) = 826 Hz) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 319.7 (d, J(P,Se) = 434 Hz), -97.9 (d, J(P,Se) = 825 Hz) ppm. Mass spectrum [APCI⁺, m/z]: 476 [M+H]⁺. Accurate mass measurement [APCI⁺, m/z]: 475.9652 [M+NH₄]⁺, calculated mass for C₁₅H₁₈N₅OPSe₂H: 475.9655.

3.2.10.1. *Se*-(2-(6-Amino-9*H*-purin-9-yl)ethyl) *O*-isopropyl phenylphosphonodiselenoate (**17**).

0.335 g as white solid in 69% yield. M.p. 141-142°C. Selected IR (KBr, cm⁻¹): 3319(m), 3141(m), 1649(s), 1589(s), 1574(m), 1480(m), 1416(m), 1327(m), 1305(m), 1246(m), 1225(m), 1098(s), 962(s), 885(m), 795(m), 733(m), 687(m), 644(m), 546(s), 494(m). ¹H NMR (DMF-d₇, δ), 8.38 (s, 1H, adenine-H), 8.25 (s, 1H, adenine-H), 8.14-8.06 (m, 2H, Ar-H), 7.81-7.73 (m, 3H, Ar-H), 7.53 (s, 2H, NH₂), 5.16-5.03 (m, 2H, OCH), 4.74-4.58 (m, 2H, NCH), 3.70-3.47 (m, 2H, SeCH₂), 1.54 (dd, J(H,H) = 6.3 Hz, J(P,H) = 1.6 Hz, 3H, CH₃) ppm. ¹³C NMR (DMF-d₇, δ), 157.1 (adenine-C), 153.3 (adenine-C), 150.5 (adenine-C), 141.7 (adenine-C), 138.3 (Ar-C), 137.0 (Ar-C), 130.6 (Ar-C), 129.3 (Ar-C), 119.9 (adenine-C), 73.9 (OCH), 43.5 (NCH₂), 32.1 (SeCH₂), 23.9 (CH₃) ppm. ³¹P NMR (DMF-d₇, δ), 76.8 (s, J(P,Se) = 434 Hz, J(P,Se) = 825 Hz) ppm. ⁷⁷Se NMR (DMF-d₇, δ), 338.6 (d, J(P,Se) = 434 Hz), -92.1 (d, J(P,Se) = 825 Hz) ppm. Mass spectrum [ESI⁺, m/z]: 490 [M+H]⁺; 512 [M+Na]⁺. Accurate mass measurement [ESI⁺, m/z]: 489.9800 [M+H]⁺, calculated mass for C₁₆H₂₀N₅OPSe₂H: 489.9814; Accurate mass measurement [ESI⁺, m/z]: 511.9615 [M+Na]⁺, calculated mass for C₁₆H₂₀N₅OPSe₂Na: 511.9634.

Acknowledgments

The authors are grateful to the University of St Andrews for financial support and the EPSRC National Mass Spectrometry Service Centre (Swansea) for mass spectral measurements.

Supplementary data

Supplementary data associated with this article can be found in the online version, at [xxxx](#)

References and Notes

- Himeno, S., and Imura, N. *J. Health Sci.* **2000**, *46*, 393–398.
- Imura, N., and Naganuma, A. in *Advances in Mercury Toxicology* (Suzuki, T., Imura, N., and Clarkson, T. W., eds) pp. 275-288, **1991**, Plenum Press, New York, NY.
- Combs, G. F., Combs, S. B. *The Role of Selenium in Nutrition*, pp. 1-532, **1986**, Academic Press, New York, NY.
- Buk, R. F., Ed. *Selenium in biology and human health*. New York: Springer-Verlag **1994**.
- Hatfield, D. K., Ed. *Selenium: its molecular biology and role in human health*. Boston: Kluwer Academic Publisher, **2001**.
- Irons, R.; Carlson, B. A.; Halfield, D. L.; Davis, C. D. *Nutr.* **2006**, *136*, 1311-1317.
- Brigelius-Flohe, R. *Free Radic. Biol. Med.* **1999**, *27*, 951-965.

8. Rotruck, J. T., Pope, A. L., Ganther, H. E., Swanson, A. B., Hafeman, D. G., Hoekstra, W. G. *Science* **1973**, *179*, 588-590.
9. Mustacich, D., Powis, G. *Biochem. J.* **2000**, *346*, 1-8.
10. Arthur, J. R., Nicol, F., Beckett, G. J. *Am. J. Clin. Nutr.* **1993**, *57*, 236S-239S.
11. Kryukov, G. V., Castellano, S., Novoselov, S. V., Lobanov, A. V., Zehrab, O., Guigo, R., Gladyshev, V. N. *Science* **2003**, *300*, 1439-1443.
12. Hatfield, D. L., Berry, M. J., Gladyshev, V. N. *Selenium: Its Molecular Biology and Role in Human Health*, 2nd Ed., pp. 1-419, **2006**, Springer, New York, NY.
13. Kiremidjian-Schumacher, L., Roy, M. *Biofactors* **2001**, *14*, 161-168.
14. Salonen, J. T., Alftan, G., Huttunen, J. K., Pikkarainen, J., Puska, P. *Lancet* **1982**, *2*, 175-179.
15. Ghose, A., Fleming, J., Harrison, P. R. *Biofactors* **2001**, *14*, 127-133.
16. El-Bayoumy, K. *Mutat. Res.* **2001**, *475*, 123-139.
17. Saenger, W. *Principles of Nucleic Acid Structure*, Springer, New York, **1984**.
18. Raboisson, P.; Lugnier, C.; Muller, C.; Reimund, J. M.; Schultz, D.; Pinna, G.; Bec, A. L.; Basaran, H.; Desaubry, L.; Gaudiot, F.; Seloum, M.; Bourguignon, J. J. *Eur. J. Med. Chem.* **2003**, *38*, 199-214.
19. Kelley, J. L.; Sokoro, F. E. *J. Med. Chem.* **1986**, *29*, 1133-1134.
20. Willard, M.; Misslin, R.; Vogel, E.; Desaubry, D.; Wermuth, C. G.; Bourguignon, J. J. *Pharmacol. Biochem. Behav.* **1989**, *35*, 85-88.
21. Bourguignon, J. J.; De'saubry, L.; Raboisson, P.; Wermuth, C.G.; Lugnier, C. *J. Med. Chem.* **1997**, *40* 1768-1770.
22. Boichot, E.; Wallace, J. L.; Germain, N.; Corbel, M.; Lugnier, C.; Lagente, V.; Bourguignon, J. J. *J. Pharmacol. Exp. Ther.* **2000**, *292*, 647-653.
23. Hichami, A.; Boichot, E.; Germain, N.; Legrand, A.; Moodley, I.; Lagente, V. *Eur. J. Pharmacol.* **1995**, *291*, 91-97.
24. Ciapetti, P.; Taddei, M. *Tetrahedron* **1998**, *54*, 11305-11318.
25. Clarembeau, M.; Cravador, A.; Dumont, W.; Hrief, L.; Lucchetti, J.; Van Ende, D. *Tetrahedron* **1985**, *41*, 4793-4812.
26. Hua, G.; Fuller, A. L.; Slawin, A. M. Z.; Woollins, J. D. *Acta Cryst.* **2010**, *E66*, o2579.
27. Gray, I. P.; Slawin, A. M. Z.; Woollins, J. D. *Dalton* **2005**, 2188-2194.
28. Crystal structure of **16**: colorless chip crystal 0.12 x 0.06 x 0.06 mm, C₁₅H₁₈N₅OPSe₂, M = 473.23, triclinic, space group P-1, a = 6.8270(5), b = 7.5233(5), c = 18.5628(13) Å, α = 81.694(9)°, β = 87.199(10)°, γ = 75.331(9), V = 912.59(12) Å³, Z = 2, ρ_{calcd} = 1.722 gcm⁻³, μ = 41.526 cm⁻¹, 6728 reflections collected, 3187 unique [R_(int) = 0.0470], R₁ = 0.1145, wR₂ = 0.3620. CCDC 1037362. Crystal structure of **17**: colorless chip crystal 0.13 x 0.10 x 0.04 mm, C₁₆H₂₀N₅OPSe₂, M = 487.26, triclinic, space group P-1, a = 8.7661(11), b = 11.9430(14), c = 18.963(2) Å, α = 97.052(9)°, β = 94.508(3)°, γ = 98.497(3), V = 1939.2(4) Å³, Z = 4, ρ_{calcd} = 1.669 gcm⁻³, μ = 39.111 cm⁻¹, 23876 reflections collected, 7077 unique [R_(int) = 0.0556], R₁ = 0.0743, wR₂ = 0.2430. CCDC 1037363.
29. Hua, G.; Du, J.; Slawin, A. M. Z.; Woollins, J. D. *J. Org. Chem.* **2014**, *79*, 3876-3886.
30. Llamas-Saiz, A. L.; Foces-Foces, C. *J. Mol. Struct.* **1990**, *238*, 367-382.
31. Fuller, A. L.; Scott-Hayward, L. A. S.; Li, Y.; Bühl, M.; Slawin, A. M. Z.; Woollins, J. D. *J. Am. Chem. Soc.* **2010**, *132*, 5799-5802.
32. CrystalClear 1.6, Rigaku Corporation, *CrystalClear Software User's Guide*, Molecular Structure Corporation, © 2000; J.W.P. Flugrath, *Acta Cryst.* **1999**, *D55*, 1718-1725.
33. SIR97, Altomare, A.; Burla, M.; Camalli, M.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A.; Polidori, G.; Spagna, R. *J. Appl. Cryst.* **1999**, *32*, 115-119.
34. DIRDIF99, Beurskens, P.T.; Admiraal, G.; Beurskens, G.; Bosman, W.P.; Israel, R.; Smits, J. M. M. *The DIRDIF-99 Program System, Technical Report of the Crystallography Laboratory*, University of Nijmegen, The Netherlands, **1999**.
35. CrystalStructure 3.8.1, *Crystal Structure Analysis Package, Rigaku and Rigaku/MS* (**2000-2006**), 9009 New Trails Dr, The Woodlands, TX 77381, USA.
36. Sheldrick, G. M. *SHELXL97. Acta Cryst.* **2008**, *A64*, 112-122.